Mesothelioma New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma Ulas D. Bayraktar, MD 2024-06-22
Non-Small Cell Lung Cancer New Drug: Repotrectinib for ROS1-fusion positive NSCLC Ulas D. Bayraktar, MD 2024-06-21
Small Cell Lung Cancer New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors Ulas D. Bayraktar, MD 2024-06-21
Uterine Cancer New Protocol: Durvalumab with CARBOplatin and PACLitaxel for Endomterial Cancer Ulas D. Bayraktar, MD 2024-06-21
Colorectal Cancer New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer Ulas D. Bayraktar, MD 2023-11-20
Mesothelioma New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma Ulas D. Bayraktar, MD 2023-11-20
Non-Small Cell Lung Cancer New Indication: Perioperative Durvalumab for NSCLC Ulas D. Bayraktar, MD 2023-11-20
Bladder Cancer New Indication: Erdafitinib in Advanced FGFR Altered Urothelial Cancer Ulas D. Bayraktar, MD 2023-11-20
Thyroid Cancer New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer Ulas D. Bayraktar, MD 2023-11-20
